Why Pfizer’s Trump Deal Is Good News for All of Big Pharma
PositiveFinancial Markets

Pfizer's recent deal with President Trump is being hailed as a positive development for the entire pharmaceutical industry. This agreement alleviates uncertainties that have been hanging over the sector, potentially leading to increased stability and growth. By fostering a more favorable environment for drug companies, this deal could encourage innovation and investment, benefiting not just Pfizer but the broader healthcare landscape.
— Curated by the World Pulse Now AI Editorial System